Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three statin drugs—atorvastatin, rosuvastatin, and simvastatin—all of which are HMG-CoA reductase inhibitors (statins) used to lower cholesterol levels. Each drug works by inhibiting the enzyme HMG-CoA reductase in the liver, reducing cholesterol synthesis and increasing clearance of low-density lipoprotein (LDL) from the bloodstream. Statins are primarily indicated for hypercholesterolemia and prevention of cardiovascular disease. While combinations of two statins have been studied for potential additive effects on lipid lowering, there is no clinical evidence or approved product combining all three agents together in a single formulation. The safety profile includes risks such as myopathy, rhabdomyolysis, liver enzyme elevations, and other side effects typical for statins[3][7][8]. Combining multiple statins increases the risk of adverse events without clear additional benefit.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on atorvastatin + rosuvastatin + simvastatin.